Abivax SA ( (FR:ABVX) ) has shared an announcement.
Abivax has announced the total number of shares and voting rights as of January 31, 2025, with 63,365,565 shares and 71,027,174 exercisable voting rights. This disclosure is part of regulatory requirements and provides transparency for stakeholders, reflecting the company’s commitment to maintaining open communication with investors and the market.
More about Abivax SA
Abivax is a clinical-stage biotechnology company focused on developing therapeutic treatments that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax’s flagship drug candidate, obefazimod (ABX464), is in phase 3 clinical development for the treatment of moderately to severely active ulcerative colitis.
YTD Price Performance: 10.64%
Average Trading Volume: 970
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €464.5M
Learn more about ABVX stock on TipRanks’ Stock Analysis page.